Study on Therapeutic Effect of Combination of Envafolimab, Lenavatinib and TACE in Advanced HCC Patients
Status:
Not yet recruiting
Trial end date:
2024-01-01
Target enrollment:
Participant gender:
Summary
This study is a single-center, open, single-arm, phase II clinical trial. Eligible HCC
patients, after signing informed consent, will receive TACE treatment. Envafolimab combined
with Lenvatinib will be started on the day of TACE, and the subsequent TACE will be performed
on demand. Patients will receive the treatment continuously until disease progression or
intolerance. Tumor imaging evaluation will be performed according to RECIST V1.1 criteria
every 6 weeks. Safety will be assessed with CTCAE 5.0. Adverse events throughout and within
30 days of the end of the study will be recorded (severe adverse events or adverse events
associated with Envafolimab will be recorded within 90 days after the end of
treatment).Treatment will last for 2 years or until disease progression, withdrawal of
informed consent, loss of visit, or death.